Cargando…

Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization

The clinical outcome of patients with a diagnosis of hormone receptor (HR)+ breast cancer has improved remarkably since the arrival of endocrine therapy. Yet, resistance to standard treatments is a major clinical challenge for breast cancer specialists and a life-threatening condition for the patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sajjadi, Elham, Venetis, Konstantinos, Piciotti, Roberto, Invernizzi, Marco, Guerini-Rocco , Elena, Haricharan, Svasti, Fusco, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130151/ https://www.ncbi.nlm.nih.gov/pubmed/34001143 http://dx.doi.org/10.1186/s12935-021-01976-y

Ejemplares similares

Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers
por: Venetis, Konstantinos, et al.
Publicado: (2020)

Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling
por: Sajjadi, Elham, et al.
Publicado: (2021)

Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients
por: Venetis, Konstantinos, et al.
Publicado: (2021)

Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management
por: Venetis, Konstantinos, et al.
Publicado: (2021)

Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
por: Sajjadi, Elham, et al.
Publicado: (2023)

PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
por: Fusco, Nicola, et al.
Publicado: (2020)

Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?
por: Haricharan, Svasti, et al.
Publicado: (2017)

Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
por: Porta, Francesca Maria, et al.
Publicado: (2023)

PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer
por: Lopez, Gianluca, et al.
Publicado: (2020)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?
por: Sajjadi, Elham, et al.
Publicado: (2020)

Improving HER2 testing reproducibility in HER2-low breast cancer
por: Sajjadi, Elham, et al.
Publicado: (2022)

Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study
por: de Sire, Alessandro, et al.
Publicado: (2021)

Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema
por: Invernizzi, Marco, et al.
Publicado: (2020)

Malignancies in Patients with Celiac Disease: Diagnostic Challenges and Molecular Advances
por: Ivanova, Mariia, et al.
Publicado: (2023)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
por: Punturi, Nindo B., et al.
Publicado: (2021)

HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes
por: Ivanova, Mariia, et al.
Publicado: (2022)

Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
por: Ivanova, Mariia, et al.
Publicado: (2023)

Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot Study
por: Invernizzi, Marco, et al.
Publicado: (2020)

Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials
por: de Sire, Alessandro, et al.
Publicado: (2022)

Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study
por: Blundo, Concetta, et al.
Publicado: (2021)

Osteoclast-like stromal giant cells in breast cancer likely belong to the spectrum of immunosuppressive tumor-associated macrophages
por: Sajjadi, Elham, et al.
Publicado: (2022)

Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
por: Pagni, Fabio, et al.
Publicado: (2019)

DNA damage repair defects as a new class of endocrine treatment resistance driver
por: Anurag, Meenakshi, et al.
Publicado: (2018)

The molecular landscape of breast mucoepidermoid carcinoma
por: Venetis, Konstantinos, et al.
Publicado: (2023)

Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis
por: Sajjadi, Elham, et al.
Publicado: (2023)

How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches
por: Ghidini, Michele, et al.
Publicado: (2021)

Mismatch repair deficiency in ovarian cancer
por: Fuh, Katherine
Publicado: (2022)

Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer
por: Lovejoy, Leann A., et al.
Publicado: (2023)

Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles
por: Sajjadi, Elham, et al.
Publicado: (2022)

Biallelic Mismatch Repair Deficiency in an Adolescent Female
por: Hildreth, Amber, et al.
Publicado: (2018)

Assessment of mismatch repair deficiency in ovarian cancer
por: Crosbie, Emma J, et al.
Publicado: (2021)

Genetic Characteristics of Mismatch Repair-deficient Glioblastoma
por: KAWAGUCHI, Kei, et al.
Publicado: (2021)

Unexplained mismatch repair deficiency: Case closed
por: Eikenboom, Ellis L., et al.
Publicado: (2022)

No Overt Clinical Immunodeficiency Despite Immune Biological Abnormalities in Patients With Constitutional Mismatch Repair Deficiency
por: Tesch, Victoria K., et al.
Publicado: (2018)

Deficient mismatch repair: Read all about it (Review)
por: RICHMAN, SUSAN
Publicado: (2015)

Low frequency of mismatch repair deficiency in gallbladder cancer
por: Goeppert, Benjamin, et al.
Publicado: (2019)

Immunoscore in mismatch repair‐proficient and ‐deficient colon cancer
por: Wirta, Erkki‐Ville, et al.
Publicado: (2017)

Clinicopathologic features of endometrial cancer with mismatch repair deficiency
por: Gordhandas, Sushmita, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cohhbjnpet4bo43g1l6mnsknvk